期刊文献+

β受体阻滞剂在心力衰竭治疗中的应用 被引量:1

Application of beta-receptor blockade in congestive heart failure
下载PDF
导出
摘要 目的 介绍β受体阻滞剂治疗充血性心力衰竭(CHF)的病理生理、作用机制、应用指征和注意事项。方法 通过查阅国内外相关文献,综述对CHF的治疗应干预神经内分泌、减轻儿茶酚胺类对心肌的直接损害,从而明确β受体阻滞剂对CHF的治疗作用。结果 在标准化治疗的基础上合理使用β受体阻滞剂对Ⅱ~Ⅲ级(按NYHA分级)心力衰竭病人疗效确切。结论 稳定的轻、中度心力衰竭,NHYA分级Ⅱ~Ⅳ级病人,标准治疗加用β受体阻滞剂,可明显改善病人预后及降低死亡率,提高生活质量。 OBJECTIVE To Introduce the mechanism, pathologic physiology, indication and precaution of applying beta-receptor blockade in congestive heart failure (CHF). METHODS We referred to domestic and international literatures to define the therapeutic function of beta-receptor blockade in CHF. RESULTS On the foundation of standardized treatment, reasonable use of beta-receptor blockade in grade II and III CHF (NYHA grade) was effective. CONCLUSIONS In the patient with stable, mild to moderate CHF, standardized treatment together with beta-receptor blockade can greatly improve the prognosis, lower the death ratio, and increase the life quality.
出处 《中南药学》 CAS 2003年第3期171-173,共3页 Central South Pharmacy
关键词 Β受体阻滞剂 心力衰竭 beta-receptor blockade congestive heart failure
  • 相关文献

参考文献13

二级参考文献49

  • 1[1]Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low - dose beta - blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol, 1985; 55(4): 471 ~ 475
  • 2[2]Waagestein F, Bristow MR, Swedberg K, et al. Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy. Lancet, 1993; 342(8885):1441~1446
  • 3[3]MERIT - HF Study Group. Effect of metoprolol CR/ XL in chronic heart failure:Metoprolol CR/ XL Randomized Intervention Trial in Congestive Heart Failure (MERIT- HF) . Lancet, 1999; 353(9169): 2001 ~ 2007
  • 4[4]Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled - release metoprolol on total mortality, hospitalizations, and well - being in patients with heart failure.The Metoprolol CR/ XL Randomized Intervention Trial in Congestive Heart Failure (MERIT- HF). JAMA, 2000; 283( 10): 1295 ~ 1302
  • 5[5]CIBIS Investigators and Committees. A randomized trim of β - blockade in heart failure:the cardiac insufficiency bisoprolol study (CIBIS). Circulation, 1994; 90(4): 1765 ~1773
  • 6[6]CIBIS - Ⅱ Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study Ⅱ(CIBIS Ⅱ): a randomized trial. Lancet, 1999; 353(9146): 9~ 13
  • 7[7]Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation, 1996; 94(11): 2800 ~ 2806
  • 8[8]Packer M, Colucci WS, Sackner - Bernstein JD, et al. Double - blind, placebo controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Circulation, 1996; 94(11): 2793 ~ 2799
  • 9[9]Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose - related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation, 1996; 94(11): 2807 ~ 2816
  • 10[10]Teerlink JR, Massie BM. Beta - adrenergic blocker mortMity trials in congestive heart failure. Am J Cardle, 1999; 84(9A): 94R ~ 102R

共引文献3078

同被引文献2

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部